CLASS II Drug recall · Reported 14 Sep 2022 · FDA Enforcement Report

Lidocaine Hydrochloride Jelly USP, 2%, Sterile tube recalled by Akorn

Akorn is recalling Lidocaine Hydrochloride Jelly USP, 2%, Sterile tube, distributed nationwide in the US. The recall was initiated on 31 Aug 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 9J36A, 9J36B, 9J39A, 9J39B, 9J39C, 9J39D, 9J39E, 9J42B, 9J42C, Exp 8/31/2022; 9K62A, 9K62B, 9K62C, Exp 9/30/2022; 9M04A, 9M04B, Exp 11/30/2022
Quantity recalled82,689 tubes

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1495-2022
FDA event ID
90813
Recalling firm
Akorn, Gurnee, IL
Classification
Class II
Status
Terminated
Recall initiated
31 Aug 2022
FDA classified
6 Sep 2022
Reported
14 Sep 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility
Drug class
Pain Medication

Timeline

31 Aug 2022Recall initiated by company
6 Sep 2022Classified by FDA+6 days
14 Sep 2022Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

cGMP Deviations: Turbidity discovered in Artificial Tears Ointment during sterility testing. Scope expanded to include other lots and products which potentially share the same root cause.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Lidocaine Hydrochloride Jelly USP, 2%, Sterile, 30mL tube, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-711-31

Where it was distributed

USA nationwide

Nationwide

Questions about this recall

Why was it recalled?

cGMP Deviations: Turbidity discovered in Artificial Tears Ointment during sterility testing. Scope expanded to include other lots and products which potentially share the same root cause.

Which lots are affected?

Lot # 9J36A, 9J36B, 9J39A, 9J39B, 9J39C, 9J39D, 9J39E, 9J42B, 9J42C, Exp 8/31/2022; 9K62A, 9K62B, 9K62C, Exp 9/30/2022; 9M04A, 9M04B, Exp 11/30/2022

Where was it sold?

USA nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 90813
ReportedClassRecallCompanyReasonWhere
CLASS IISodium Chloride Ophthalmic Ointment USP, 5%, Sterile recalled by AkornAkornSterilityNationwide

More recalls from Akorn

All 192

Other Lidocaine Jelly recalls

All 4